In 1992, Baxter (Baxalta) publicized the first recombinant coagulation factor VIII. Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Wyeth, etc. By Jun. 2018, no domestic recombinant coagulation factor VIII has been launched. In May 2018, China's local biopharmaceutical company Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. had received Approval Document for Clinical Trials of recombinant human coagulation factor VIII for injection issued by the CFDA.
Recombinant human coagulation factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY 300 million in 2017, and the CAGR reached 65.2% from 2009 to 2017. Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.
Forecasts that with the development of China's economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of recombinant human coagulation factor VIII in China will continue to increase from 2018 to 2022. After 2022, there is possibility that Chinese companies may launch recombinant human coagulation factor VIII.
Topics Covered
- Development of Recombinant Human Coagulation Factor VIII in China
- Sales of Recombinant Human Coagulation Factor VIII in China
- Sale price of Recombinant Human Coagulation Factor VIII in the Chinese market
- Manufacturers of Recombinant Human Coagulation Factor VIII in the Chinese market
- Research progress of Chinese companies on Recombinant Human Coagulation Factor VIII
- Chinese market prospects on Recombinant Human Coagulation Factor VIII from 2018 to 2022
Table of Contents
Samples
LOADING...
Companies Mentioned
- Bayer
- Baxalta
- Wyeth
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
